XTX Topco Ltd Decreases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

XTX Topco Ltd cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 20.8% in the fourth quarter, HoldingsChannel reports. The firm owned 6,866 shares of the company’s stock after selling 1,799 shares during the quarter. XTX Topco Ltd’s holdings in Neurocrine Biosciences were worth $937,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Caprock Group LLC purchased a new position in shares of Neurocrine Biosciences in the 4th quarter worth $236,000. Charles Schwab Investment Management Inc. grew its position in Neurocrine Biosciences by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company’s stock worth $104,089,000 after acquiring an additional 15,266 shares in the last quarter. Tri Ri Asset Management Corp bought a new stake in Neurocrine Biosciences during the third quarter worth approximately $3,236,000. Oakworth Capital Inc. purchased a new stake in Neurocrine Biosciences during the fourth quarter valued at approximately $379,000. Finally, Synergy Asset Management LLC bought a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $996,000. Institutional investors own 92.59% of the company’s stock.

Insider Activity

In other news, Director Kevin Charles Gorman sold 146,105 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the completion of the sale, the director now owns 514,596 shares in the company, valued at approximately $76,911,518.16. This represents a 22.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Matt Abernethy sold 1,283 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.87, for a total value of $196,132.21. Following the completion of the sale, the chief financial officer now directly owns 32,681 shares of the company’s stock, valued at $4,995,944.47. The trade was a 3.78 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 167,906 shares of company stock worth $24,671,530. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Piper Sandler restated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Wednesday, March 26th. William Blair reiterated an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 20th. Finally, Wedbush dropped their target price on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $161.86.

Neurocrine Biosciences Stock Up 4.1 %

Shares of NASDAQ:NBIX opened at $100.10 on Thursday. The company has a market capitalization of $9.90 billion, a price-to-earnings ratio of 30.43, a price-to-earnings-growth ratio of 0.77 and a beta of 0.33. The firm has a 50 day moving average of $109.01 and a 200 day moving average of $122.58. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its Board of Directors has authorized a stock repurchase program on Friday, February 21st that allows the company to repurchase $500.00 million in shares. This repurchase authorization allows the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.